Effects of bioreductive agents, tirapazamine and mitomycin c, on quiescent cell populations in solid tumors, evaluated by micronucleus assay

Japanese Journal of Cancer Research

Volumn 88, Issue 9, 1997, Pages 907-914

  Masunaga, Shin Ichiro ^a   Ono, Koji ^a   Hori, Hitoshi ^a   Shibata, Toru ^b   Suzuki, Minoru ^a   Kinashi, Yuko ^a   Takagaki, Masao ^a   Akaboshi, Mitsuhiko ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Hypoxic cell; Mitomycin C; Quiescent cell; Tirapazamine

Indexed keywords

BROXURIDINE; CISPLATIN; CYTOCHALASIN B; MITOMYCIN C; TIRAPAZAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINESIS; FEMALE; GAMMA IRRADIATION; IMMUNOFLUORESCENCE; INTRAPERITONEAL DRUG ADMINISTRATION; MICRONUCLEUS TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SOLID TUMOR; TUMOR CELL;

EID: 0030657937     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00468.x     Document Type: Article

References (25)

1. Brown, J. M. and Siim, B. G. Hypoxia-specific cytotoxins in cancer therapy. Semin. Radiat. Oncol., 6, 22-36 (1996).
2. Kennedy, K. A., Teicher, B. A., Rockwell, S. and Sartorelli, A. C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol., 29, 1-8 (1979).
3. Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K. and Lee, W. W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammmalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12, 1239-1242 (1986).
4. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67, 1163-1170 (1993).
5. Koch, C. J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res., 53, 3992-3997 (1993).
6. Holden, S. A., Teicher, B. A., Ara, G., Herman, T. S. and Coleman, C. N. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine flbrosarcoma. J. Natl. Cancer Inst., 84, 187-193 (1992).
7. Dorie, M. J. and Brown, J. M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res., 53, 4633-4636 (1993).
8. Langmuir, V. K., Rooker, J. A., Osen, M., Mendonca, H. L. and Laderoute, K. R. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res., 54, 2845-2847 (1994).
9. Doherty, N., Hancock, S. L., Kaye, S., Coleman, C. N., Shulman, L., Marquez, C., Mariscal, C., Rampling, R., Senan, S. and Roemaling, R. V. Muscle crampling in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int. J. Radiat. Oncol. Biol. Phys., 29, 379-382 (1994).
10. Johnson, C. A., Kilpatrick, D., von Roemeling, R., Langer, C., Graham, M. A., Greenslade, D., Kennedy, G., Keenan, E. and O'Dwyer, P. J. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J. Clin. Oncol., 15, 773-780 (1997).
11. Luk, C. K., Keng, P. C. and Sutherland, R. M. Regrowth and radiation sensitivity of quiescent cells isolated from EMT6/Ro-fed plateau monolayers. Cancer Res., 45, 1020-1025 (1985).
12. Wallen, C. A., Ridinger, D. N. and Dethlefsen, L. A. Heterogeneity of X-ray cytotoxicity in proliferating and quiescent murine mammary carcinoma cells. Cancer Res., 45, 3064-3069 (1985).
13. Jackson, R. C. The problem of the quiescent cancer cell. Adv. Enzyme Regul., 29, 27-46 (1989).
14. Dethlefsen, L. A. In quest of the quaint quiescent cells. In "Radiation Biology in Cancer Research," ed. R. E. Meyn and H. R. Withers, pp. 415-435 (1980). Raven Press, New York.
15. Sartorelli, A. C. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res., 48, 775-778 (1988).
16. Steel, G. G. Cell population kinetics of tumors in experimental animals. In "Growth Kinetics of Tumours," ed. G. G. Steel, pp. 146-216 (1977). Clarendon Press, Oxford.
17. Masunaga, S., Ono, K. and Abe, M. A method for selective measurement of the radiosensitivity of quiescent cells in solid tumors - combination of immunofluorescence staining to BrdU and micronucleus assay -. Radiat. Res., 125, 243-247 (1991).
18. Masunaga, S., Ono, K., Akaboshi, M., Kawai, K., Akuta, K., Takagaki, M., Suzuki, M., Kinashi, Y. and Abe, M. An attempt to enhance chemosensitivity of quiescent cell populations in solid tumors by combined treatment with nicotinamide and carbogen. J. Cancer Res. Clin. Oncol., 122, 533-540 (1996).
19. Bremner, J. C. M., Btratford, I. J., Bowler, J. and Adams, G. E. Bioreductive drugs and the selective induction of tumor hypoxia. Br. J. Cancer, 61, 717-721 (1990).
20. Brown, J.M. and Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50, 7745-7749 (1990).
21. Ono, K., Wandl, E. O., Tsutsui, K., Sasai, K. and Abe, M. The correlation between cell survival curve and dose response curve of micronucleus (MN) frequency. Strahlenther. Onkol., 165, 824-827 (1989).
22. Mitchell, J., Morstyn, G., Russo, A., Kinsella, T., Fornace, A., McPherson, S. and Glatstein, E. Differing sensitivity to fluorescent light in Chinese hamster cells containing equally incorporated quantities of BUdR versus IUdR. Int. J. Radiat. Oncol. Biol. Phys., 10, 1447-1451 (1984).
23. Fenech, M. and Morley, A. A. Measurement of micronuclei in lymphocytes. Mutat. Res., 147, 29-36 (1985).
24. Akaboshi, M., Kawai, K., Kinashi, Y., Masunaga, S. and Ono, K. Relationship between cell-killing efficiency and number of platinum atoms binding to DNA, RNA, and protein molecules in Hela cells treated with cis-diammine-(glycolato)platinum (II). Jpn. J. Cancer Res., 87, 178-183 (1996).
25. Kallinowski, F., Schlenger, K. H., Runkel, S., Kloes, S., Stohrer, M., Okunnieff, P. and Vaupel, P. Blood flow, metabolism, cellular microenvironment and growth rate of human tumour xenografts. Cancer Res., 49, 3759-3764 (1989).